Cogstate test displays effective treatment choice for schizophrenia Medical technology company Cogstate continues to strengthen its position as an important partner for measuring cognition in important studies around the world, with results from a schizophrenia study using Cogstate's test published in a significant scientific journal. In a peer reviewed paper published in the European Neuropsychopharmacology journal co-authored by Cogstate Chief Research Officer Dr Paul Maruff, it had been reported that Lurasidone, an atypical antipsychotic medication, improved cognitive function of schizophrenia individuals, as measured by the Cogstate tests, more than the control group significantly eli lilly .